Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.63 |
| ▸ | DRD3 | P35462 | 15/20 | 0.63 |
| ▸ | HTR2A | P28223 | 11/20 | 0.63 |
| ▸ | HTR1A | P08908 | 4/20 | 0.63 |
| ▸ | DRD4 | P21917 | 4/20 | 0.63 |
| ▸ | HTR2B | P41595 | 4/20 | 0.63 |
| ▸ | HTR2C | P28335 | 3/20 | 0.63 |
| ▸ | DRD1 | P21728 | 1/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bp-14979 SCHEMBL24005999 | 1.00 | DRD2 (0.63) | DRD2DRD3HTR2AHTR1ADRD4 | |
| Bp-14979 SCHEMBL29730885 | 1.00 | DRD2 (0.63) | DRD2DRD3HTR2AHTR1ADRD4 | |
| Bp-14979 SCHEMBL13630506 | 1.00 | DRD2 (0.63) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL13630394 | 0.95 | DRD2 (0.57) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL4490376 | 0.95 | DRD2 (0.57) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL25535948 | 0.91 | DRD2 (0.66) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL13629925 | 0.91 | DRD2 (0.60) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL4483671 | 0.91 | DRD2 (0.60) | DRD2DRD3HTR2AHTR1ADRD4 | |
| Bp-14979 SCHEMBL17220515 | 0.90 | DRD2 (0.55) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL13630505 | 0.88 | DRD2 (0.64) | DRD2DRD3HTR2ACHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582648-B2 | Method for treating central nervous system disorders using dopamine D3 partial agonists | BIOPROJET PHARMA (FR) | 2026-03-24 | — | — | US | claimed |
| US-20230165852-A1 | METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS USING DOPAMINE D3 PARTIAL AGONISTS | BIOPROJET PHARMA (FR) | 2023-06-01 | — | — | US | claimed |
| EP-4146214-A1 | USE OF DOPAMINE D3 PARTIAL AGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | BIOPROJET Pharma (FR) | 2023-03-15 | — | — | EP | claimed |
| CN-115715195-A | Use of partial dopamine D3 agonists for the treatment of central nervous system disorders | 生物计划制药公司 | 2023-02-24 | — | — | CN | claimed |
| EP-3906927-B1 | USE OF DOPAMINE D3 PARTIAL AGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | BIOPROJET PHARMA (FR) | 2022-05-25 | — | — | EP | claimed |
| EP-3906927-A1 | USE OF DOPAMINE D3 PARTIAL AGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | BIOPROJET Pharma (FR) | 2021-11-10 | — | — | EP | claimed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | claimed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | claimed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | claimed |
| US-12582648-B2 | Method for treating central nervous system disorders using dopamine D3 partial agonists | BIOPROJET PHARMA (FR) | 2026-03-24 | — | — | US | disclosed |
| US-20230165852-A1 | METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS USING DOPAMINE D3 PARTIAL AGONISTS | BIOPROJET PHARMA (FR) | 2023-06-01 | — | — | US | disclosed |
| EP-4146214-A1 | USE OF DOPAMINE D3 PARTIAL AGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | BIOPROJET Pharma (FR) | 2023-03-15 | — | — | EP | disclosed |
| CN-115715195-A | Use of partial dopamine D3 agonists for the treatment of central nervous system disorders | 生物计划制药公司 | 2023-02-24 | — | — | CN | disclosed |
| EP-3906927-B1 | USE OF DOPAMINE D3 PARTIAL AGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | BIOPROJET PHARMA (FR) | 2022-05-25 | — | — | EP | disclosed |
| WO-2021224235-A1 | USE OF DOPAMINE D3 PARTIAL AGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | BIOPROJET PHARMA (FR) | 2021-11-11 | — | — | WO | disclosed |
| EP-3906927-A1 | USE OF DOPAMINE D3 PARTIAL AGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | BIOPROJET Pharma (FR) | 2021-11-10 | — | — | EP | disclosed |
| EP-3906927-A1 | USE OF DOPAMINE D3 PARTIAL AGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | BIOPROJET Pharma (FR) | 2021-11-10 | — | — | EP | disclosed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | DRD2 4/4885DRD3 1/4885HTR2A 225/4885 |
| US-12582648-B2 | Method for treating central nervous system disorders using dopamine D3 partial agonists | DRD3, DRD2, DRD1 | DRD2 2/4885DRD3 1/4885HTR2A 209/4885 |
| US-20230165852-A1 | METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS USING DOPAMINE D3 PARTIAL AGONISTS | DRD3, DRD2, DRD1 | DRD2 2/4885DRD3 1/4885HTR2A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.